Are there significant gains ahead for one (or both) of these innovative biotechs?

英特利亚一款针对罕见水肿疾病的 CRISPR 基因编辑疗法三期临床试验达到主要终点，成为基因编辑领域里程碑事件。 该疗法依托诺贝尔奖级 CRISPR 技术编辑 DNA，用于治疗遗传性血管水肿 —— 一种可引发致命性水肿发作的遗传病。 公司已向美国 FDA 启动滚动式递交上市申请，若获批，计划于 2027 年正式上市。 美国马萨诸塞州剑桥市，英特利亚疗法公司外景及标识。 英特利亚疗法宣布，其用于治疗 ...

CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a medicine for a pair of rare blood diseases, which became the first ...

Q1 results and earnings estimate revisions put CRISPR Therapeutics (CRSP) in focus CRISPR Therapeutics (CRSP) has moved back onto investors’ radar after reporting a Q1 2026 net loss of US$122.9 ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...

Finding a quality mid-cap stock to invest in can lead to huge returns for investors down the road. These are the types of companies that are still in their early growth stages and that can possess ...

CRISPR Therapeutics' lone approved product isn't generating much revenue yet. The company has made little clinical progress elsewhere in recent years. Though there are risks, if CRISPR Therapeutics' ...

Over the past five years, CRISPR Therapeutics' (NASDAQ: CRSP) shares have significantly lagged broader equities. That's despite the company earning approval for its first commercialized medicine, ...